What is the Study of Tamoxifen and Raloxifene (STAR)?
The Study of Tamoxifen and Raloxifene (STAR) is a clinical trial (a research study conducted with people) designed to see how the drug raloxifene (Evista) compares with the drug tamoxifen (Nolvadex) in reducing the incidence of breast cancer in women who are at an increased risk of developing the disease. Researchers with the National Surgical Adjuvant Breast and Bowel Project (NSABP) are conducting the study at more than 400 centers across the United States, Puerto Rico, and Canada. The study is primarily funded by the National Cancer Institute (NCI), the U.S. government’s main agency for cancer research.
The Study of Tamoxifen and Raloxifene (STAR) is a clinical trial (a research study conducted with people) comparing the drug raloxifene (Evista®) with the drug tamoxifen (Nolvadex®) in reducing the incidence of breast cancer in postmenopausal women who are at an increased risk of developing the disease. Researchers with the National Surgical Adjuvant Breast and Bowel Project (NSABP) are conducting the study at more than 500 centers across the United States, Canada, and Puerto Rico. The study is funded primarily by the National Cancer Institute (NCI) – part of the National Institutes of Health. NCI is the U.S. Government’s main agency for cancer research. 2. Who participated in STAR? Women at increased risk of developing breast cancer, who had gone through menopause, and were at least 35 years old took part in STAR. STAR began enrolling participants in 1999. Enrollment was closed on November 4, 2004, with 19,747 women recruited.
